About TIB Molbiol
TIB Molbiol is a Healthcare company based in Berlin (Germany) founded in 1990, and was acquired by Roche in September 2021. Kits and reagents for research and diagnostics are supplied. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified.
Company details
Founded in 1990 and headquartered in Berlin, Germany, TIB Molbiol operates in the biotechnology sector. Reagents and kits are developed for molecular diagnostics and research applications. Services encompass DNA primer and probe synthesis, PCR assays, and specialized LightMix kits for detecting pathogens such as Influenza A H5N1. Testing solutions are also provided for hematology markers, genetic mutations, and polymorphisms across various laboratories.
- Headquarters Berlin, Germany
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website tib-molbiol.de
- Social LinkedIn
- Acquired by Roche (Sep 2021)
Investors in TIB Molbiol
TIB Molbiol has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for TIB Molbiol
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TIB Molbiol
5 people are tracked at TIB Molbiol (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Natalie Pauly | Head Of Research And Development | Leadership |
Marcus Droege | General Manager TIB Molbiol Syntheselabor | Leadership |
Dr. Marcus Droege | General Manager | Leadership |
Ariel Viña Rodríguez | Research Scientist | Team |
Claudia Hasche | Commercial Services Specialist | Team |
Complete people profiles for TIB Molbiol
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TIB Molbiol
2 dated milestones of TIB Molbiol across 31 years, from founding to its latest funding, stage changes and deals.
- Founded TIB Molbiol is founded.
- Exit Acquired by Roche.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tib Molbiol
Complete news archive for TIB Molbiol
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TIB Molbiol
TIB Molbiol was founded in 1990.
TIB Molbiol is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Founded in 1990 and headquartered in Berlin, Germany, TIB Molbiol operates in the biotechnology sector. Reagents and kits are developed for molecular diagnostics and research applications. Services encompass DNA primer and probe synthesis, PCR assays, and specialized LightMix kits for detecting pathogens such as Influenza A H5N1. Testing solutions are also provided for hematology markers, genetic mutations, and polymorphisms across various laboratories.
TIB Molbiol has 1 investor. Key investors include Roche.
Yes. TIB Molbiol was acquired by Roche in September 2021.